| Original language | English (US) |
|---|---|
| Pages (from-to) | 499-501 |
| Number of pages | 3 |
| Journal | Journal of the American Academy of Child and Adolescent Psychiatry |
| Volume | 44 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2005 |
Funding
Disclosure: Dr. Kratochvil receives grant support from or is a consultant to or member of the speaker's bureau of AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Forest, Cephalon, McNeil Pharmaceutical, Novartis Pharmaceutical, and Organon; Dr. Lake receives grant support from or is a member of the speaker's bureau of AstraZeneca, Johnson & Johnson, and McNeil Pharmaceutical. Dr. Pliszka receives support from or is a member of the speaker's bureau of Eli Lilly and Company, Shire Laboratories Inc., and McNeil Pharmaceutical; and Dr. Walkup receives grant support from or is a consultant or member of the speaker's bureau for Abbott, Eli Lilly and Company, Janssen Pharmaceutical, and Pfizer.
ASJC Scopus subject areas
- Psychiatry and Mental health
- Developmental and Educational Psychology
